Concert composes Celgene deal for $300m per song
This article was originally published in Scrip
Executive Summary
Concert Pharmaceuticals will concentrate on advancing its internal pipeline of deuterium-modified compounds and its ongoing partnerships with the upfront fees the Lexington, Massachusetts-based company earned from a new strategic collaboration with Celgene.